telmisartan has been researched along with Insulin Resistance in 101 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 38 (37.62) | 29.6817 |
| 2010's | 59 (58.42) | 24.3611 |
| 2020's | 4 (3.96) | 2.80 |
| Authors | Studies |
|---|---|
| Bigge, CF; Casimiro-Garcia, A; Chen, J; Davis, JA; Dudley, DA; Edmunds, JJ; Ellis, T; Esmaeil, N; Filzen, GF; Flynn, D; Geyer, A; Heemstra, RJ; Jalaie, M; Ohren, JF; Ostroski, R; Schaum, RP; Stoner, C | 1 |
| Kang, TS; Kim, BK; Kim, JY; Lee, CJ; Lee, SH; Park, S; Sung, JH | 1 |
| Foster, T; García-Fiñana, M; Jaki, T; Kemp, GJ; Khoo, S; Kolamunnage-Dona, R; Pirmohamed, M; Pushpakom, S; Spowart, C; Taylor, C; Williamson, P | 1 |
| He, J; Huang, C; Huang, H; Huang, Y; Li, R; Li, Y; Liu, Q; Tang, Q; Wu, T; Zhang, G; Zhang, J; Zhang, Z; Zhao, Y; Zhou, J | 1 |
| Basiak, M; Krysiak, R; Okopień, B; Szkróbka, W | 1 |
| Adaikalakoteswari, A; Back, DJ; Kumar, S; McTernan, P; Owen, A; Pirmohamed, M; Pushpakom, SP; Tripathi, G | 1 |
| Borém, LMA; Brandi, IV; Lelis, DF; Neto, JFR; Santos, SHS | 1 |
| Cui, X; Di, Y; Fang, T; Li, G; Li, Y; Shen, N; Tian, F; Xi, P; Xie, Y | 1 |
| Budak, F; Guclu, M; Kiyici, S; Sigirli, D; Tuncel, E | 1 |
| Cheon, HG; Choi, HE; Jeon, EJ; Kim, DY; Lee, NH | 1 |
| Arimitsu, M; Kamei, N; Koike, Y; Naruse, M; Sakamoto, R; Yambe, Y | 1 |
| Kazdová, L; Kurtz, TW; Landa, V; Mlejnek, P; Pravenec, M; Silhavy, J; Simáková, M; Zídek, V | 1 |
| Anand, SS; Chetty, VT; Damjanovic, S; Gerstein, H; Sharma, AM; Singh, N; Yusuf, S | 1 |
| Li, LY; Luo, R; Sun, LT; Tian, FS; Xiong, HL; Zhao, ZQ; Zheng, XL | 1 |
| Barkhausen, J; Hübel, N; Mildner, M; Müller-Fielitz, H; Raasch, W; Vogt, FM | 1 |
| Takagi, H; Umemoto, T | 3 |
| Bowden, J; Jennison, C; Stallard, N; Wason, J | 1 |
| Graus-Nunes, F; Mandarim-de-Lacerda, CA; Penna-de-Carvalho, A; Rabelo-Andrade, J; Souza-Mello, V | 1 |
| Bader, M; Barkhausen, J; Raasch, W; Santos, RA; Schuchard, J; Schuster, F; Stölting, I; Thorns, C; Vogt, FM; Winkler, M | 1 |
| Abouzied, MM; Heeba, GH; Khalifa, MM; Rabie, EM | 1 |
| D'Angelo, A; Dario Ragonesi, P; Derosa, G; Franzetti, I; Maffioli, P; Querci, F | 1 |
| Liu, Y; Wang, B; Wang, Q; Wang, X; Wang, Y; Yang, Q; Zhang, C; Zhang, Q | 1 |
| Gaikwad, AB; Goru, SK; Kadakol, A; Malek, V; Pandey, A | 1 |
| Hampson, LV; Jaki, T | 1 |
| García-Fiñana, M; Jaki, T; Kemp, GJ; Khoo, S; Kolamunnage-Dona, R; Pirmohamed, M; Pushpakom, SP; Spowart, C; Taylor, C; Vora, J; Whitehead, J; Williamson, P | 1 |
| Dezortová, M; Hájek, M; Hill, M; Kratochvílová, S; Pelikánová, T; Škoch, A; Švehlíková, E; Wohl, P | 1 |
| Ali, EF; Mahdi, EA; Mahmoud, FA; Mostafa-Hedeab, G; Shahataa, MG | 1 |
| Aizawa, K; Arakawa, Y; Fujimura, A; Ushijima, K; Yanagihara, H | 1 |
| Ano, N; Atsuda, K; Inoue, G; Irie, J; Kitaoka, A; Shiono, K; Toda, K; Yamada, S | 1 |
| Fujimoto, Y; Hinoi, T; Kajiwara, S; Matsuo, S; Ono, T; Shichijo, T; Tomohiro, Y; Yamamoto, S | 1 |
| Arita, M; Furuta, M; Sanke, T; Shimajiri, Y; Yamana, A | 1 |
| Matsui, T; Nakamura, K; Yamagishi, SI | 1 |
| Enjoji, M; Higuchi, N; Kato, M; Kohjima, M; Kotoh, K; Nakamuta, M; Nakashima, M | 1 |
| Georgescu, EF | 1 |
| Fischer, P; Masnatta, LD; Pesiney, C; Ramirez, AJ; Sanchez, RA | 1 |
| Brillante, DG; Brillante, RE; Howes, LG; O'Sullivan, AJ | 1 |
| Elisaf, MS; Liberopoulos, EN; Rizos, CV | 1 |
| Aini, W; Ebihara, K; Hirata, M; Kusakabe, T; Li, Y; Miyamoto, L; Murray, M; Nakao, K; Rong, X; Zhao, M | 1 |
| Itoh, T; Minami, Y; Nakamura, M; Satoh, M; Tabuchi, T; Takahashi, Y | 1 |
| Limor, R; Oron, Y; Rosenthal, T; Stern, N; Younis, F; Zangen, S | 1 |
| Fujita, T; Fuke, Y; Matsumoto, K; Satomura, A; Wada, Y | 1 |
| Ebihara, K; Kusakabe, T; Kuwahara, K; Li, Y; Murray, M; Nakao, K; Naowaboot, J; Rong, X; Zhao, M | 1 |
| Aguila, MB; Cardoso-de-Lemos, FS; de Carvalho, L; Gregório, BM; Mandarim-de-Lacerda, CA; Souza-Mello, V | 1 |
| Kondo, K; Nomura, Y; Oiso, Y; Ozaki, N; Sobajima, H | 1 |
| Hill, M; Klementová, M; Kopecký, J; Kratochvílová, S; Krusinová, E; Mlejnek, P; Neskudla, T; Pelikánová, T; Pravenec, M; Vrbíková, J; Wohl, P; Zídková, K | 1 |
| Kazawa, T; Kuroki, N; Kuwabara, M; Maruki, T; Odagaki, Y; Toyoshima, R; Yamashita, H; Yoda, H | 1 |
| Awata, T; Ikebukuro, K; Inukai, K; Ito, D; Katayama, S; Kurihara, S; Ono, H; Sumita, T; Watanabe, M | 1 |
| Davidai, G; Henry, R; Hsueh, W; Mudaliar, S | 1 |
| Clemenz, M; Foryst-Ludwig, A; Hartge, M; Hess, K; Kintscher, U; Marx, N; Sprang, C; Unger, T | 1 |
| Kajioka, T; Kitahara, Y; Miura, K; Takeuchi, M; Yamagishi, S | 1 |
| Comi-Diaz, C; Macias-Batista, A; Martinez-Martin, FJ; Pedrianes-Martin, P; Rodriguez-Rosas, H; Soriano-Perera, P | 1 |
| Costo, A; Crespo, L; Doncel, C; Fernandez Toro, JM; Fraile, J; Rivas, MD; Sanchez Muñoz-Torrero, JF; Zamorano, J | 1 |
| Ikeda, N; Kanno, Y; Kobayashi, K; Ohno, Y; Okada, H; Suzuki, H; Takenaka, T | 1 |
| Aminuddin, A; Bukhari, A; Fujisaka, S; Ikutani, M; Kanatani, Y; Kobayashi, M; Nagai, Y; Senda, S; Suzuki, H; Tabuchi, Y; Takasaki, I; Takatsu, K; Tobe, K; Tsuneyama, K; Usui, I; Yamazaki, Y | 1 |
| Feng, W; Li, G; Tu, L; Wang, D; Xu, X; Yin, X | 1 |
| Matsuura, K; Mori, Y; Tanaka, T; Utsunomiya, K; Yokoyama, J | 1 |
| De Caterina, R; Di Iorio, A; Falasca, K; Mancino, P; Ucciferri, C; Vecchiet, J | 1 |
| Poolsup, N; Prasit, T; Suksomboon, N | 1 |
| Sahebkar, A | 1 |
| Hu, TJ; Huang, GZ; Tang, YH; Wang, BY; Zhang, B; Zhang, L; Zhang, XY; Zhong, Y | 1 |
| Higaki, J; Horiuchi, M; Iwanami, J; Jing, F; Min, LJ; Mogi, M; Ohshima, K; Tsukuda, K | 1 |
| Heidbreder, M; Jöhren, O; Landolt, J; Müller-Fielitz, H; Raasch, W; Vogt, FM; Werth, S | 1 |
| Adamczak, M; Chudek, J; Kubik, M; Wiecek, A | 1 |
| Horiguchi, CS; Makino, H; Miyoshi, T; Murakami, K; Nakamura, Y; Ogawa, D; Sasaki, M; Uchida, HA; Wada, J | 1 |
| Di Iorio, A; Falasca, K; Mancino, P; Ucciferri, C; Vecchiet, J | 1 |
| Arao, T; Mori, H; Nishida, K; Okada, Y; Tanaka, Y | 2 |
| Jaki, T; Wason, JM | 1 |
| Merk, D; Schubert-Zsilavecz, M | 1 |
| Ando, H; Fujimura, A; Ishikawa-Kobayashi, E; Maekawa, T; Nozawa, M; Shiga, T; Takuma, M; Ushijima, K | 1 |
| Cheng, S; Li, H; Li, J; Li, X; Yuan, L | 1 |
| Chen, J; Feng, X; He, H; Li, L; Liu, D; Luo, Z; Pu, Y; Wang, P; Yu, H; Zhao, Y; Zhong, J; Zhu, Z | 1 |
| Engeli, S; Gorzelniak, K; Janke, J; Luft, FC; Sharma, AM | 1 |
| Kurtz, TW; Pershadsingh, HA | 1 |
| Clasen, R; Janke, J; Kintscher, U; Schupp, M; Unger, T | 1 |
| Doggrell, SA | 1 |
| Takeuchi, M; Yamagishi, S | 1 |
| Kintscher, U; Unger, T | 1 |
| Clasen, R; Clemenz, M; Foryst-Ludwig, A; Kintscher, U; Krikov, M; Schupp, M; Sprang, C; Thöne-Reineke, C; Unger, T | 1 |
| Inoue, H; Takenaka, K; Yamagishi, S | 1 |
| Pershadsingh, HA | 1 |
| Sharma, AM | 1 |
| Kurtz, TW | 1 |
| Ding, DY; Ji, H; Li, YQ; Ye, XL; Zhang, YH | 1 |
| Ando, H; Fujimura, A | 1 |
| Göke, B; Nagel, JM; Parhofer, KG; Tietz, AB | 1 |
| Appel, D; Benndorf, RA; Böger, RH; Maas, R; Rudolph, T; Schulze, F; Schwedhelm, E; Silberhorn, E | 1 |
| Chazova, IE; Duishvili, DE; Mamyrbaeva, KM; Masenko, VP; Mychka, VB | 1 |
| Hassan, H; Negro, R | 1 |
| Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Fogari, R; Gravina, A; Piccinni, MN; Pricolo, F; Ragonesi, PD; Salvadeo, SA | 1 |
| Shimabukuro, M; Shimabukuro, T; Tanaka, H | 1 |
| Burnier, M; Dulloo, AG; Montani, JP; Perregaux, C; Zanchi, A | 1 |
| Bahadir, MA; Bahadir, O; Oguz, A; Uzunlulu, M | 1 |
| Kariv, N; Nachman, R; Rosenthal, T; Younis, F; Zangen, S | 1 |
| Chen, XY; Du, GT; Ji, H; Li, YQ; Meng, ZK; Shi, WB; Tian, J; Zhang, YH | 1 |
| Ichikawa, Y | 1 |
| Maruki, T; Toyoshima, R; Yamashita, H; Yoda, H | 1 |
| Nakamura, K; Yamagishi, S | 1 |
| Asano, A; Chujo, D; Kobayashi, J; Mabuchi, H; Muramoto, H; Ohnishi, A; Sakai, S; Shintaku-Kubota, M; Yagi, K; Yamagishi, M | 1 |
14 review(s) available for telmisartan and Insulin Resistance
| Article | Year |
|---|---|
The role of the angiotensin II type I receptor blocker telmisartan in the treatment of non-alcoholic fatty liver disease: a brief review.
Topics: Angiotensin II Type 1 Receptor Blockers; Humans; Insulin Resistance; Non-alcoholic Fatty Liver Disease; Renin-Angiotensin System; Telmisartan | 2018 |
A meta-analysis of randomized trials of telmisartan versus active controls for insulin resistance in hypertensive patients.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Blood Pressure; Humans; Hypertension; Insulin Resistance; Randomized Controlled Trials as Topic; Telmisartan; Treatment Outcome | 2014 |
Possible molecular mechanisms by which angiotensin II type 1 receptor blockers (ARBs) prevent the development of atrial fibrillation in insulin resistant patients.
Topics: Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Benzimidazoles; Benzoates; Humans; Insulin Resistance; Telmisartan | 2008 |
Angiotensin receptor blockers in the treatment of NASH/NAFLD: could they be a first-class option?
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Biphenyl Compounds; Fatty Liver; Humans; Insulin Resistance; Losartan; Metabolic Syndrome; Renin-Angiotensin System; Telmisartan; Tetrazoles | 2008 |
Are the pleiotropic effects of telmisartan clinically relevant?
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Body Fat Distribution; Cholesterol, LDL; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucose; Heart Failure; Humans; Hypertension; Hypertrophy, Left Ventricular; Insulin Resistance; Kidney; PPAR gamma; Randomized Controlled Trials as Topic; Telmisartan | 2009 |
Systematic review of the effect of telmisartan on insulin sensitivity in hypertensive patients with insulin resistance or diabetes.
Topics: Adiponectin; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Benzoates; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Humans; Hyperglycemia; Hyperinsulinism; Hypertension; Insulin Resistance; PPAR gamma; Randomized Controlled Trials as Topic; Telmisartan | 2012 |
Telmisartan increases adiponectin levels: a meta-analysis and meta-regression of randomized head-to-head trials.
Topics: Adiponectin; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Coronary Disease; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Humans; Insulin Resistance; Randomized Controlled Trials as Topic; Telmisartan; Treatment Outcome | 2012 |
Telmisartan improves insulin sensitivity: a meta-analysis of randomized head-to-head trials.
Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Diabetes Mellitus, Type 2; Humans; Insulin Resistance; Randomized Controlled Trials as Topic; Telmisartan | 2012 |
Telmisartan - killing two birds with one stone.
Topics: 3T3-L1 Cells; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Biphenyl Compounds; Diabetes Mellitus, Type 2; Disease Models, Animal; Humans; Hypertension; Insulin Resistance; Irbesartan; Mice; PPAR gamma; Rats; Rats, Zucker; Telmisartan; Tetrazoles | 2004 |
Vascular protection in diabetes: a pharmacological view of angiotensin II type 1 receptor blockers.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Insulin Resistance; PPAR gamma; Renin-Angiotensin System; Telmisartan | 2005 |
Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-gamma.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biphenyl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Insulin Resistance; Irbesartan; Losartan; Metabolic Syndrome; PPAR gamma; Telmisartan; Tetrazoles | 2006 |
The obese patient with diabetes mellitus: from research targets to treatment options.
Topics: Adipogenesis; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Benzoates; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Complications; Diabetes Mellitus, Type 2; Humans; Insulin Resistance; Obesity; Renin-Angiotensin System; Telmisartan; Weight Loss | 2006 |
New treatment strategies for patients with hypertension and insulin resistance.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atherosclerosis; Benzimidazoles; Benzoates; Coronary Artery Disease; Diabetes Mellitus, Type 2; Humans; Hypertension; Insulin Resistance; Metabolic Syndrome; PPAR gamma; Renin-Angiotensin System; Telmisartan | 2006 |
Telmisartan, its potential therapeutic implications in cardiometabolic disorders.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Cardiovascular Diseases; Diabetic Retinopathy; Humans; Insulin Resistance; PPAR gamma; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Renin-Angiotensin System; Telmisartan | 2006 |
33 trial(s) available for telmisartan and Insulin Resistance
| Article | Year |
|---|---|
Effects of high-intensity statin combined with telmisartan versus amlodipine on glucose metabolism in hypertensive atherosclerotic cardiovascular disease patients with impaired fasting glucose: A randomized multicenter trial.
Topics: Amlodipine; Atherosclerosis; Cardiovascular Diseases; Fasting; Glucose; Heart Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Insulin Resistance; Prediabetic State; Rosuvastatin Calcium; Telmisartan | 2022 |
TAILoR (TelmisArtan and InsuLin Resistance in Human Immunodeficiency Virus [HIV]): An Adaptive-design, Dose-ranging Phase IIb Randomized Trial of Telmisartan for the Reduction of Insulin Resistance in HIV-positive Individuals on Combination Antiretroviral
Topics: Benzimidazoles; Benzoates; HIV; HIV Infections; Humans; Insulin Resistance; Telmisartan | 2020 |
Even Short-Term Telmisartan Treatment Ameliorated Insulin Resistance But Had No Influence on Serum Adiponectin and Tumor Necrosis Factor-Alpha Levels in Hypertensive Patients with Metabolic Syndrome.
Topics: Adiponectin; Adolescent; Adult; Aged; Antihypertensive Agents; Drug Administration Schedule; Female; Humans; Hypertension; Insulin Resistance; Male; Metabolic Syndrome; Middle Aged; Telmisartan; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha; Young Adult | 2019 |
Effects of azilsartan compared with telmisartan on insulin resistance in patients with essential hypertension and type 2 diabetes mellitus: An open-label, randomized clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Benzimidazoles; Blood Pressure; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Insulin Resistance; Male; Middle Aged; Oxadiazoles; Telmisartan | 2019 |
Metabolic effects of telmisartan in subjects with abdominal obesity: a prospective randomized controlled trial.
Topics: Adiponectin; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Female; Humans; Insulin Resistance; Lipid Metabolism; Male; Middle Aged; Obesity, Abdominal; Prospective Studies; Single-Blind Method; Telmisartan | 2014 |
Comparison of the effects of barnidipine+losartan compared with telmisartan+hydrochlorothiazide on several parameters of insulin sensitivity in patients with hypertension and type 2 diabetes mellitus.
Topics: Adipokines; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Diuretics; Double-Blind Method; Drug Combinations; Female; Glucose Clamp Technique; Humans; Hydrochlorothiazide; Hypertension; Insulin Resistance; Losartan; Male; Middle Aged; Nifedipine; Telmisartan | 2015 |
Telmisartan and Insulin Resistance in HIV (TAILoR): protocol for a dose-ranging phase II randomised open-labelled trial of telmisartan as a strategy for the reduction of insulin resistance in HIV-positive individuals on combination antiretroviral therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Antiretroviral Therapy, Highly Active; Benzimidazoles; Benzoates; Clinical Protocols; Drug Therapy, Combination; Female; HIV Infections; Humans; Insulin Resistance; Male; Middle Aged; Research Design; Telmisartan; Young Adult | 2015 |
Intramyocellular lipid content in subjects with impaired fasting glucose after telmisartan treatment, a randomised cross-over trial.
Topics: Adipokines; Adiponectin; Adult; Benzimidazoles; Benzoates; Blood Glucose; Calorimetry; Cholesterol; Cross-Over Studies; Cytoplasm; Double-Blind Method; Glucose Clamp Technique; Humans; Insulin; Insulin Resistance; Lipids; Magnetic Resonance Spectroscopy; Male; Metabolic Syndrome; Middle Aged; Muscles; Telmisartan | 2016 |
Telmisartan but not candesartan affects adiponectin expression in vivo and in vitro.
Topics: 3T3-L1 Cells; Adipocytes; Adiponectin; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Benzoates; Biphenyl Compounds; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; In Vitro Techniques; Insulin Resistance; Male; Mice; Middle Aged; PPAR gamma; RNA, Messenger; Telmisartan; Tetrazoles; Treatment Outcome | 2008 |
Telmisartan, an angiotensin II type 1 receptor blocker, improves coronary microcirculation and insulin resistance among essential hypertensive patients without left ventricular hypertrophy.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Blood Glucose; Blood Pressure; Coronary Circulation; Echocardiography; Female; Heart Rate; Humans; Hypertension; Hypertrophy, Left Ventricular; Insulin Resistance; Lipids; Male; Microcirculation; Middle Aged; Telmisartan | 2008 |
The angiotensin II receptor blocker telmisartan improves insulin resistance and has beneficial effects in hypertensive patients with type 2 diabetes and poor glycemic control.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Hypertension; Insulin Resistance; Male; Middle Aged; Telmisartan; Treatment Outcome | 2008 |
Therapeutic effect of ARBs on insulin resistance and liver injury in patients with NAFLD and chronic hepatitis C: a pilot study.
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Benzimidazoles; Benzoates; Fatty Liver; Female; Hepatitis C, Chronic; Homeostasis; Humans; Hypertension; Imidazoles; Incidence; Insulin Resistance; Japan; Male; Middle Aged; Pilot Projects; Telmisartan; Tetrazoles | 2008 |
Telmisartan improves insulin resistance in high renin nonmodulating salt-sensitive hypertensives.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Glucose; Blood Pressure; C-Reactive Protein; Cross-Over Studies; Female; Humans; Hypertension; Insulin Resistance; Lipids; Male; Oxidative Stress; PPAR gamma; Ramipril; Renin; Salt Tolerance; Telmisartan | 2008 |
Effects of cardiovascular angiotensin II type 1 receptor blockade on nitric oxide synthase inhibition in patients with insulin resistance syndrome.
Topics: Adult; Angiotensin II; Arteries; Benzimidazoles; Benzoates; Blood Pressure; Cardiovascular System; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Hemodynamics; Humans; Insulin Resistance; Male; Metabolic Syndrome; Nitric Oxide Synthase; omega-N-Methylarginine; Photoplethysmography; Receptor, Angiotensin, Type 1; Telmisartan; Vascular Resistance | 2009 |
Prospective, randomized, single-blind comparison of effects of 6 months of treatment with telmisartan versus enalapril on high-molecular-weight adiponectin concentrations in patients with coronary artery disease.
Topics: Adiponectin; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; C-Reactive Protein; Coronary Angiography; Coronary Artery Disease; Double-Blind Method; Enalapril; Female; Follow-Up Studies; Humans; Insulin Resistance; Male; Molecular Weight; Prospective Studies; Telmisartan | 2009 |
Comparison of the effects of three angiotensin II receptor type 1 blockers on metabolic parameters in hypertensive patients with type 2 diabetes mellitus.
Topics: Adiponectin; Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Glucose; Blood Pressure; C-Reactive Protein; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Glycated Hemoglobin; Humans; Hypertension; Insulin Resistance; Lipids; Male; Middle Aged; Telmisartan; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2010 |
Effect of telmisartan on selected adipokines, insulin sensitivity, and substrate utilization during insulin-stimulated conditions in patients with metabolic syndrome and impaired fasting glucose.
Topics: Adipokines; Adult; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Glucose; Glucose Clamp Technique; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metabolic Syndrome; Middle Aged; Telmisartan | 2010 |
Effects of telmisartan on insulin resistance in Japanese type 2 diabetic patients.
Topics: Adiponectin; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Cholesterol, HDL; Diabetes Mellitus, Type 2; Female; Homeostasis; Humans; Hypertension; Insulin Resistance; Japan; Lipoproteins, LDL; Male; Metabolic Syndrome; Middle Aged; Obesity; Oxidative Stress; PPAR gamma; Telmisartan; Tetrazoles | 2010 |
Telmisartan effects on insulin resistance in obese or overweight adults without diabetes or hypertension.
Topics: Adolescent; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Diabetes Complications; Diabetes Mellitus; Double-Blind Method; Female; Humans; Hypertension; Insulin Resistance; Male; Middle Aged; Obesity; Overweight; Telmisartan | 2010 |
Effects of manidipine and its combination with an ACE inhibitor on insulin sensitivity and metabolic, inflammatory and prothrombotic markers in hypertensive patients with metabolic syndrome: the MARCADOR study.
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Biomarkers; Blood Pressure; Dihydropyridines; Drug Combinations; Female; Humans; Hypertension; Insulin Resistance; Lisinopril; Male; Metabolic Syndrome; Middle Aged; Nitrobenzenes; Piperazines; Prospective Studies; Spain; Telmisartan | 2011 |
Influence of telmisartan on insulin response after glucose loading in obese patients with hypertension: ARB trial of hypertension in obese patients with hyperinsulinemia assessed by oral glucose tolerance test (ATHLETE).
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Glucose; Blood Pressure; Female; Glucose; Glucose Tolerance Test; Humans; Hyperinsulinism; Hypertension; Insulin Resistance; Male; Obesity; Telmisartan; Tetrazoles; Valine; Valsartan | 2011 |
Effects of telmisartan on insulin resistance and visceral fat distribution in Chinese hypertensive patients with obesity.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; China; Female; Humans; Hypertension; Insulin Resistance; Intra-Abdominal Fat; Male; Middle Aged; Obesity; Telmisartan | 2011 |
The effects of telmisartan treatment on the abdominal fat depot in patients with metabolic syndrome and essential hypertension: Abdominal fat Depot Intervention Program of Okayama (ADIPO).
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Blood Glucose; Blood Pressure; Body Mass Index; Body Weight; Female; Humans; Hypertension; Insulin Resistance; Intra-Abdominal Fat; Male; Metabolic Syndrome; Middle Aged; PPAR gamma; Subcutaneous Fat; Telmisartan; Tetrazoles; Tomography, X-Ray Computed; Treatment Outcome; Valine; Valsartan; Waist Circumference | 2013 |
Telmisartan at 80 mg/day increases high-molecular-weight adiponectin levels and improves insulin resistance in diabetic patients.
Topics: Adipocytes; Adiponectin; Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Blood Glucose; Blood Pressure; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Humans; Hypertension; Insulin; Insulin Resistance; Lipid Metabolism; Male; Middle Aged; PPAR gamma; Telmisartan; Triglycerides | 2012 |
Antihypertensive and metabolic effects of high-dose olmesartan and telmisartan in type 2 diabetes patients with hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Benzimidazoles; Benzoates; C-Reactive Protein; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Resistance; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypoglycemic Agents; Imidazoles; Insulin Resistance; Male; Middle Aged; Telmisartan; Tetrazoles | 2013 |
The effect of telmisartan on glucose and lipid metabolism in nondiabetic, insulin-resistant subjects.
Topics: Adiponectin; Adult; Angiotensin Receptor Antagonists; Benzimidazoles; Benzoates; Blood Glucose; C-Peptide; Cross-Over Studies; Double-Blind Method; Glucose Tolerance Test; Homeostasis; Humans; Insulin; Insulin Resistance; Lipid Metabolism; Lipids; Middle Aged; Overweight; Telmisartan; Treatment Outcome | 2006 |
Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension.
Topics: Adiponectin; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Body Mass Index; Calcium Channel Blockers; Cohort Studies; Female; Humans; Hypertension; Insulin Resistance; Male; Middle Aged; Nisoldipine; PPAR gamma; Telmisartan | 2006 |
The effects of telmisartan and amlodipine on metabolic parameters and blood pressure in type 2 diabetic, hypertensive patients.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Humans; Hypertension; Insulin Resistance; Middle Aged; PPAR gamma; Telmisartan | 2006 |
Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Glucose; Blood Pressure; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Irbesartan; Leptin; Lipids; Male; Middle Aged; Rosiglitazone; Telmisartan; Tetrazoles; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2006 |
Effects of telmisartan on fat distribution in individuals with the metabolic syndrome.
Topics: Adipose Tissue, White; Adult; Aged; Amlodipine; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Aorta; Benzimidazoles; Benzoates; Biomarkers; Blood Glucose; Blood Pressure; Body Fat Distribution; Calcium Channel Blockers; Female; Glucose Tolerance Test; Humans; Hypertension; Insulin; Insulin Resistance; Intra-Abdominal Fat; Male; Metabolic Syndrome; Middle Aged; Prospective Studies; Research Design; Telmisartan; Tomography, X-Ray Computed; Treatment Outcome; Vascular Resistance | 2007 |
Effects of telmisartan and losartan on insulin resistance in hypertensive patients with metabolic syndrome.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Blood Glucose; Blood Pressure; Cholesterol, HDL; Fasting; Female; Humans; Hypertension; Insulin Resistance; Losartan; Male; Metabolic Syndrome; Middle Aged; Telmisartan | 2007 |
Comparative effects of telmisartan and valsartan on insulin resistance in hypertensive patients with metabolic syndrome.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Female; Humans; Hypertension; Insulin Resistance; Male; Metabolic Syndrome; Middle Aged; Telmisartan; Tetrazoles; Valine; Valsartan | 2007 |
Telmisartan treatment decreases visceral fat accumulation and improves serum levels of adiponectin and vascular inflammation markers in Japanese hypertensive patients.
Topics: Adiponectin; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Blood Pressure; C-Reactive Protein; Cholesterol, HDL; Female; Humans; Hypertension; Insulin Resistance; Interleukin-6; Intra-Abdominal Fat; Japan; Male; Middle Aged; PPAR gamma; Regional Blood Flow; Telmisartan; Vasculitis | 2007 |
54 other study(ies) available for telmisartan and Insulin Resistance
| Article | Year |
|---|---|
Discovery of a series of imidazo[4,5-b]pyridines with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ.
Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Biological Availability; Blood Glucose; Crystallography, X-Ray; Drug Partial Agonism; Humans; Hypoglycemic Agents; Imidazoles; Insulin Resistance; Male; Models, Molecular; PPAR gamma; Pyridines; Radioligand Assay; Rats; Rats, Inbred SHR; Stereoisomerism; Structure-Activity Relationship; Transcriptional Activation; Triglycerides | 2011 |
Telmisartan attenuates obesity-induced insulin resistance via suppression of AMPK mediated ER stress.
Topics: 3T3-L1 Cells; AMP-Activated Protein Kinases; Angiotensin II Type 1 Receptor Blockers; Animals; Endoplasmic Reticulum Stress; Enzyme Activation; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Obesity; Telmisartan | 2020 |
The Impact of Telmisartan on Cardiometabolic Risk Factors in Hypertensive Male Siblings of Women With Polycystic Ovary Syndrome.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Blood Pressure; Body Weights and Measures; C-Reactive Protein; Cardiometabolic Risk Factors; Cardiovascular Diseases; Female; Humans; Hypertension; Insulin Resistance; Lipids; Male; Middle Aged; Polycystic Ovary Syndrome; Siblings; Telmisartan; Testosterone | 2021 |
Telmisartan reverses antiretroviral-induced adipocyte toxicity and insulin resistance in vitro.
Topics: Adipocytes; Adipokines; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Cell Differentiation; Insulin Resistance; Lipid Metabolism; Mice; PPAR gamma; Telmisartan | 2018 |
Effects of telmisartan on TNFα induced PPARγ phosphorylation and insulin resistance in adipocytes.
Topics: 3T3-L1 Cells; Adipocytes; Angiotensin II Type 1 Receptor Blockers; Animals; Insulin Resistance; Mice; Phosphorylation; PPAR gamma; Telmisartan; Tumor Necrosis Factor-alpha | 2018 |
Telmisartan induces browning of fully differentiated white adipocytes via M2 macrophage polarization.
Topics: Adipocytes, Brown; Adipocytes, White; Adipose Tissue, White; Angiotensin II Type 1 Receptor Blockers; Animals; Catecholamines; Cell Differentiation; Clodronic Acid; Culture Media, Conditioned; Humans; Insulin Resistance; Macrophage Activation; Macrophages; Male; Mice; Obesity; PPAR gamma; RAW 264.7 Cells; Receptors, Cytoplasmic and Nuclear; Telmisartan | 2019 |
Tissue-specific peroxisome proliferator activated receptor gamma expression and metabolic effects of telmisartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Blood Glucose; Disease Models, Animal; Hypertension; Insulin Resistance; Mice; Mice, Knockout; PPAR gamma; Telmisartan | 2013 |
Angiotensin II receptor blocker telmisartan prevents new-onset diabetes in pre-diabetes OLETF rats on a high-fat diet: evidence of anti-diabetes action.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Blood Glucose; Blood Pressure; Body Weight; Cytokines; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Gene Expression; Hypoglycemic Agents; Inflammation; Insulin Resistance; Male; Metformin; Pioglitazone; Rats; Rats, Inbred OLETF; Telmisartan; Thiazolidinediones | 2013 |
Chronic blockade of angiotensin AT₁ receptors improves cardinal symptoms of metabolic syndrome in diet-induced obesity in rats.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Obesity Agents; Antihypertensive Agents; Behavior, Animal; Benzimidazoles; Benzoates; Diet, High-Fat; Dietary Sucrose; Drug Therapy, Combination; Energy Intake; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Insulin Resistance; Leptin; Male; Metabolic Syndrome; Obesity; Random Allocation; Rats; Rats, Inbred SHR; Telmisartan; Weight Gain | 2014 |
A multi-stage drop-the-losers design for multi-arm clinical trials.
Topics: Benzimidazoles; Benzoates; Controlled Clinical Trials as Topic; HIV Infections; Humans; Insulin Resistance; Patient Selection; Research Design; Sample Size; Telmisartan; Treatment Outcome | 2017 |
Enhanced pan-peroxisome proliferator-activated receptor gene and protein expression in adipose tissue of diet-induced obese mice treated with telmisartan.
Topics: Adipose Tissue; Animals; Benzimidazoles; Benzoates; Diet, High-Fat; Gene Expression; Insulin Resistance; Male; Mice; Mice, Obese; Obesity; Peroxisome Proliferator-Activated Receptors; Telmisartan | 2014 |
Lack of weight gain after angiotensin AT1 receptor blockade in diet-induced obesity is partly mediated by an angiotensin-(1-7)/Mas-dependent pathway.
Topics: Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Genetically Modified; Benzimidazoles; Benzoates; Diet; Energy Intake; Energy Metabolism; Insulin Resistance; Leptin; Male; Obesity; Peptide Fragments; Proto-Oncogene Mas; Proto-Oncogene Proteins; Rats; Receptors, G-Protein-Coupled; Signal Transduction; Telmisartan; Weight Gain; Weight Loss | 2015 |
Comparative effects of Aliskiren and Telmisartan in high fructose diet-induced metabolic syndrome in rats.
Topics: Amides; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Glucose; Fructose; Fumarates; Insulin Resistance; Male; Metabolic Syndrome; Rats; Rats, Wistar; Telmisartan; Treatment Outcome | 2015 |
[Effects of telmisartan on resistin expression in a rat model of nonalcoholic steatohepatitis and insulin resistance].
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Benzimidazoles; Benzoates; Cholesterol; Diet, High-Fat; Disease Models, Animal; Insulin; Insulin Resistance; Male; Non-alcoholic Fatty Liver Disease; Rats; Rats, Sprague-Dawley; Resistin; Telmisartan; Triglycerides | 2015 |
Insulin sensitizing and cardioprotective effects of Esculetin and Telmisartan combination by attenuating Ang II mediated vascular reactivity and cardiac fibrosis.
Topics: Angiotensin II; Animals; Benzimidazoles; Benzoates; Cardiotonic Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fibrosis; Heart Diseases; Insulin Resistance; Male; Rats; Rats, Wistar; Telmisartan; Treatment Outcome; Umbelliferones; Vasoconstriction | 2015 |
Designing multi-arm multi-stage clinical trials using a risk-benefit criterion for treatment selection.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Clinical Trials, Phase III as Topic; Computer Simulation; Decision Making; Endpoint Determination; HIV Seropositivity; Humans; Insulin Resistance; Models, Statistical; Patient Safety; Research Design; Sample Size; Telmisartan | 2016 |
Effects of telmisartan and pioglitazone on high fructose induced metabolic syndrome in rats.
Topics: Animals; Benzimidazoles; Benzoates; Blood Glucose; Drug Therapy, Combination; Fructose; Hypoglycemic Agents; Insulin Resistance; Male; Metabolic Syndrome; Pioglitazone; Rats; Rats, Sprague-Dawley; Telmisartan; Thiazolidinediones; Treatment Outcome | 2016 |
Effects of telmisartan and olmesartan on insulin sensitivity and renal function in spontaneously hypertensive rats fed a high fat diet.
Topics: 3T3-L1 Cells; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Diet, High-Fat; Imidazoles; Insulin Resistance; Kidney; Mice; Rats; Rats, Inbred SHR; Telmisartan; Tetrazoles | 2016 |
An adipose tissue-independent insulin-sensitizing action of telmisartan: a study in lipodystrophic mice.
Topics: Adipose Tissue; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Blood Glucose; Disease Models, Animal; Dose-Response Relationship, Drug; Energy Metabolism; Female; Glucose Tolerance Test; Insulin; Insulin Resistance; Lipodystrophy; Liver; Mice; Mice, Transgenic; Organ Size; PPAR gamma; Telmisartan; Transcription Factors; Triglycerides | 2009 |
Telmisartan ameliorates hyperglycemia and metabolic profile in nonobese Cohen-Rosenthal diabetic hypertensive rats via peroxisome proliferator activator receptor-gamma activation.
Topics: Adiponectin; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Blood Pressure; Humans; Hyperglycemia; Hypertension; Insulin; Insulin Resistance; Leptin; PPAR gamma; Rats; Rats, Inbred SHR; Rosiglitazone; Telmisartan; Thiazolidinediones; Tumor Necrosis Factor-alpha; Weight Gain | 2010 |
Alterations of insulin resistance and the serum adiponectin level in patients with type 2 diabetes mellitus under the usual antihypertensive dosage of telmisartan treatment.
Topics: Adiponectin; Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Enzyme-Linked Immunosorbent Assay; Female; Humans; Hypertension; Insulin Resistance; Male; Middle Aged; Prospective Studies; Telmisartan; Treatment Outcome | 2010 |
Angiotensin II type 1 receptor-independent beneficial effects of telmisartan on dietary-induced obesity, insulin resistance and fatty liver in mice.
Topics: Adipocytes; Adipose Tissue, White; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Blood Glucose; Cell Size; Diet, High-Fat; Fatty Liver; Insulin; Insulin Resistance; Leptin; Lipids; Liver; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Mice, Knockout; Muscle, Skeletal; Obesity, Abdominal; Organ Size; PPAR gamma; Receptor, Angiotensin, Type 1; Telmisartan; Triglycerides | 2010 |
Comparative effects of telmisartan, sitagliptin and metformin alone or in combination on obesity, insulin resistance, and liver and pancreas remodelling in C57BL/6 mice fed on a very high-fat diet.
Topics: Adipocytes; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Dietary Fats; Dipeptidyl-Peptidase IV Inhibitors; Drug Evaluation, Preclinical; Drug Therapy, Combination; Energy Intake; Glucose Tolerance Test; Hypoglycemic Agents; Insulin Resistance; Liver; Male; Metabolic Syndrome; Metformin; Mice; Mice, Inbred C57BL; Obesity; Pancreas; Pyrazines; Sitagliptin Phosphate; Telmisartan; Triazoles | 2010 |
Angiotensin II type 1 receptor blockers improve insulin sensitivity in patients with schizophrenia being treated with olanzapine.
Topics: Angiotensin II Type 1 Receptor Blockers; Antipsychotic Agents; Benzimidazoles; Benzoates; Benzodiazepines; Female; Humans; Hyperinsulinism; Insulin Resistance; Male; Middle Aged; Olanzapine; Receptor, Angiotensin, Type 1; Schizophrenia; Telmisartan; Tetrazoles; Valine; Valsartan | 2011 |
PPARgamma activation attenuates T-lymphocyte-dependent inflammation of adipose tissue and development of insulin resistance in obese mice.
Topics: Abdominal Fat; Animals; Anti-Inflammatory Agents; Antigens, Differentiation; Benzimidazoles; Benzoates; CD3 Complex; Chemokine CXCL12; Chemotaxis; Dietary Fats; Disease Models, Animal; Inflammation; Insulin Resistance; Lymphocyte Activation; Macrophages; Male; Mice; Mice, Inbred C57BL; Obesity; PPAR gamma; Rosiglitazone; T-Lymphocytes; Telmisartan; Thiazolidinediones; Time Factors | 2010 |
Combination therapy with nateglinide and telmisartan ameliorates insulin resistance in zucker Fatty rats by suppressing advanced glycation end product receptor axis.
Topics: Animals; Benzimidazoles; Benzoates; Cyclohexanes; Disease Models, Animal; Down-Regulation; Drug Therapy, Combination; Glycation End Products, Advanced; Humans; Insulin Resistance; Liver; Male; Nateglinide; Phenylalanine; Rats; Rats, Zucker; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Telmisartan | 2011 |
Telmisartan improves insulin resistance in patients with low cytokine levels.
Topics: Adult; Benzimidazoles; Benzoates; Biomarkers; Blood Glucose; Cytokines; Female; Humans; Hypertension; Insulin Resistance; Male; Metabolic Syndrome; Middle Aged; Telmisartan | 2011 |
Telmisartan lowers home blood pressure and improves insulin resistance without correlation between their changes.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Humans; Hypertension; Insulin; Insulin Resistance; Lipids; Middle Aged; Telmisartan | 2011 |
Telmisartan improves insulin resistance and modulates adipose tissue macrophage polarization in high-fat-fed mice.
Topics: Adipocytes; Adipose Tissue; Angiotensin II Type 1 Receptor Blockers; Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Benzimidazoles; Benzoates; Body Weight; CD11c Antigen; Cell Adhesion Molecules; Cell Size; Dietary Fats; Epididymis; Flow Cytometry; Gene Expression Profiling; Gene Expression Regulation; Glucose; Insulin Resistance; Lectins, C-Type; Macrophages; Male; Mice; Mice, Inbred C57BL; Obesity; Oligonucleotide Array Sequence Analysis; Receptors, Cell Surface; Reverse Transcriptase Polymerase Chain Reaction; Telmisartan; Tumor Necrosis Factor-alpha | 2011 |
Telmisartan protects against insulin resistance by attenuating inflammatory response in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; C-Reactive Protein; Chemokine CCL2; Cytokines; Dietary Fats; I-kappa B Proteins; Inflammation; Insulin Resistance; Male; NF-KappaB Inhibitor alpha; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; RNA, Messenger; Telmisartan | 2011 |
Antihypertensive and metabolic effects of telmisartan in hypertensive HIV-positive patients.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Cardiovascular Diseases; Cystatin C; Endothelin-1; HIV Seropositivity; Humans; Hypertension; Insulin Resistance; Interleukin-18; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; PPAR gamma; Risk Factors; Telmisartan; Triglycerides | 2011 |
Metabolic improvement by telmisartan beyond angiotensin receptor blockade: role of adipokines.
Topics: Adipokines; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Humans; Insulin Resistance; Obesity; Resistin; Telmisartan; Tumor Necrosis Factor-alpha | 2011 |
Roles of interleukin 17 in angiotensin II type 1 receptor-mediated insulin resistance.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antibodies, Anti-Idiotypic; Benzimidazoles; Benzoates; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucose; Insulin Resistance; Interleukin-17; Male; Mice; Mice, Inbred C57BL; Muscle, Skeletal; Receptor, Angiotensin, Type 1; Telmisartan | 2012 |
Improved insulin sensitivity after long-term treatment with AT1 blockers is not associated with PPARγ target gene regulation.
Topics: Adipocytes; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Biphenyl Compounds; Body Weight; Gene Expression Regulation; Glucose Tolerance Test; Hemodynamics; Hypothalamus; Insulin; Insulin Resistance; Male; Models, Biological; Obesity; PPAR gamma; Rats; Rats, Inbred SHR; Telmisartan; Tetrazoles | 2012 |
Telmisartan improves cardiometabolic profile in obese patients with arterial hypertension.
Topics: Adult; Aged; Benzimidazoles; Benzoates; Female; Humans; Hypertension; Insulin Resistance; Male; Metabolome; Middle Aged; Obesity; Telmisartan | 2012 |
Microalbuminuria and hypertension in HIV-infected patients: a preliminary study of telmisartan.
Topics: Adult; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Antiretroviral Therapy, Highly Active; Benzimidazoles; Benzoates; Biomarkers; Blood Pressure; Endothelium, Vascular; Glomerular Filtration Rate; HIV Infections; Humans; Hypertension; Insulin Resistance; Italy; Kidney; Male; Middle Aged; Telmisartan; Time Factors; Treatment Outcome | 2012 |
Optimal design of multi-arm multi-stage trials.
Topics: Angiotensin-Converting Enzyme Inhibitors; Anti-Retroviral Agents; Benzimidazoles; Benzoates; Bias; Clinical Trials as Topic; Computer Simulation; Drug Therapy, Combination; Endpoint Determination; HIV Infections; Humans; Insulin Resistance; Research Design; Sample Size; Telmisartan | 2012 |
[Non-agonist inhibitors of Cdk5-dependent phosphorylation of PPAR as insulin sensitizers in the future?].
Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cyclin-Dependent Kinase 5; Diabetes Mellitus, Type 2; Humans; Hypertriglyceridemia; Hypoglycemic Agents; Insulin Resistance; Peroxisome Proliferator-Activated Receptors; Phosphorylation; Telmisartan | 2012 |
Effects of telmisartan and valsartan on insulin sensitivity in obese diabetic mice.
Topics: Adiponectin; Adipose Tissue; Animals; Benzimidazoles; Benzoates; Body Weight; Diabetes Mellitus; Eating; Fatty Acid Synthases; Fatty Acid-Binding Proteins; Gene Expression Regulation; Homeostasis; Insulin Resistance; Interleukin-6; Male; Mice; Mice, Obese; PPAR gamma; RNA, Messenger; Telmisartan; Tetrazoles; Tumor Necrosis Factor-alpha; Valine; Valsartan | 2013 |
Blockade of renin angiotensin system increased resistance to STZ-induced diabetes in rats with long-term high-fat diet.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Benzimidazoles; Benzoates; Blood Glucose; Caspase 3; Diabetes Mellitus, Experimental; Diet, High-Fat; Glucose Clamp Technique; Immunohistochemistry; Inflammation Mediators; Insulin; Insulin Resistance; Insulin-Secreting Cells; Interleukin-1beta; Male; NF-kappa B; Prediabetic State; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Reverse Transcriptase Polymerase Chain Reaction; Streptozocin; Telmisartan; Time Factors | 2012 |
Telmisartan improves insulin resistance of skeletal muscle through peroxisome proliferator-activated receptor-δ activation.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Benzoates; Biological Transport; Cell Line; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Glucose; Hypoglycemic Agents; Insulin Resistance; Ligands; Mice; Mice, Knockout; Muscle, Skeletal; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; PPAR gamma; Random Allocation; Signal Transduction; Telmisartan; Up-Regulation | 2013 |
Angiotensin blockade prevents type 2 diabetes by formation of fat cells.
Topics: Adipocytes; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Benzoates; Cell Differentiation; Clinical Trials as Topic; Diabetes Mellitus; Diabetes Mellitus, Type 2; Disease Models, Animal; Humans; Hypoglycemic Agents; Insulin Resistance; Obesity; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Telmisartan | 2002 |
Insulin-sensitizing effects of telmisartan: implications for treating insulin-resistant hypertension and cardiovascular disease.
Topics: Benzimidazoles; Benzoates; Cardiovascular Diseases; Humans; Hypertension; Insulin Resistance; Male; Middle Aged; Telmisartan | 2004 |
Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity.
Topics: 3T3 Cells; Acrylates; Adipocytes; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Biphenyl Compounds; Cell Differentiation; Genes, Reporter; Imidazoles; Insulin Resistance; Irbesartan; Losartan; Luciferases; Mice; PC12 Cells; Rats; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Recombinant Fusion Proteins; Retinoid X Receptors; Telmisartan; Tetrazoles; Thiophenes; Transcription Factors; Transfection | 2004 |
Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Cardiovascular Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 2; Humans; Hypertension; Insulin Resistance; PPAR gamma; Renin-Angiotensin System; Telmisartan; Tetrazoles; Valine; Valsartan | 2005 |
PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin.
Topics: 3T3-L1 Cells; Adipocytes; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Biphenyl Compounds; Cycloheximide; Insulin Resistance; Irbesartan; Mice; Obesity; PPAR gamma; Protein Processing, Post-Translational; Protein Synthesis Inhibitors; Rats; Rats, Zucker; Receptor, Angiotensin, Type 2; Telmisartan; Tetrazoles | 2005 |
Role of insulin-sensitizing property of telmisartan, a commercially available angiotensin II type 1 receptor blocker in preventing the development of atrial fibrillation.
Topics: Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Benzimidazoles; Benzoates; Humans; Insulin Resistance; Telmisartan | 2006 |
Metabolic effects of telmisartan in spontaneously hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; CD36 Antigens; Gene Expression Regulation; Glucose; Glucose Tolerance Test; Hypertension; Insulin Resistance; Liver; Male; Muscle, Skeletal; Rats; Rats, Inbred SHR; Telmisartan; Triglycerides | 2006 |
[PPARgamma-activating properties of angiotensin receptor blockers].
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Arteriosclerosis; Benzimidazoles; Benzoates; Biphenyl Compounds; Humans; Insulin Resistance; Irbesartan; Metabolic Syndrome; PPAR gamma; Randomized Controlled Trials as Topic; Telmisartan; Tetrazoles | 2006 |
[The role of telmisartan in the treatment of metabolic syndrome].
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biomarkers; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Body Mass Index; Cholesterol; Female; Follow-Up Studies; Glucose Tolerance Test; Humans; Insulin; Insulin Resistance; Male; Metabolic Syndrome; PPAR gamma; Telmisartan; Treatment Outcome | 2006 |
Telmisartan prevents the glitazone-induced weight gain without interfering with its insulin-sensitizing properties.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Benzoates; Drug Evaluation, Preclinical; Drug Interactions; Insulin; Insulin Resistance; Male; Obesity; Rats; Rats, Sprague-Dawley; Rats, Zucker; Telmisartan; Thiazolidinediones; Weight Gain | 2007 |
Telmisartan in the treatment of Cohen-Rosenthal Diabetic Hypertensive rats: the benefit of PPAR-gamma agonism.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Disease Models, Animal; Hypertension; Hypoglycemic Agents; Insulin Resistance; Male; PPAR gamma; Rats; Rats, Inbred SHR; Telmisartan | 2007 |
WB1106, a novel nitric oxide-releasing derivative of telmisartan, inhibits hypertension and improves glucose metabolism in rats.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Aorta, Thoracic; Benzimidazoles; Benzoates; Blood Pressure; Cyclic GMP; Diet; Dietary Carbohydrates; Dietary Fats; Glucose; Insulin Resistance; Male; Muscle Contraction; Muscle Relaxation; Nitric Oxide; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Rats, Sprague-Dawley; Telmisartan; Vasoconstriction; Vasoconstrictor Agents | 2007 |
Telmisartan, an angiotensin II type-1 receptor blocker, improved insulin resistance in a schizophrenic patient treated with olanzapine: a case report.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Antipsychotic Agents; Benzimidazoles; Benzoates; Benzodiazepines; Female; Humans; Insulin Resistance; Olanzapine; Schizophrenia; Telmisartan | 2008 |